Skip to content
To the full analysis

Vicore Pharma Holding stock: balance sheet and debt

VICO.ST
$1.10Closing price of 12 Nov 2026MEQIRI Score 38 out of 100

Vicore Pharma Holding has a debt to equity ratio of 0.

Daily figure as of 13 Nov 2026

Debt / Equity
0
Interest coverage
−8.5x
Current ratio
10.31
Cash & equivalents
$117.14M
Total assets
$122.29M
Equity ratio
89.8%
Goodwill
not reported separately
Net debt
−$117.14M
More cash than debt

Total assets and equity ratio

How large the balance sheet of Vicore Pharma Holding AB (publ) is, how much of it is equity and how much is goodwill from acquisitions.

Equity ratio

Figures as a table
YearTotal assetsGoodwill and intangible assetsof which goodwillEquity ratioNet debt
2012$3.84K$1.59Knot split out68.5%−$371.91
2013$5.11M$2.77M$1.08M78.5%−$694.38K
2014$5.95M$3.72M$1.92M90.4%−$21.06K
2015$8.95M$4.29Mnot split out91.8%−$2.52M
2016$8.19M$5.64Mnot split out92.6%−$427.76K
2017$11.99M$7.22Mnot split out94.5%−$2.41M
2018$30.24M$6.94Mnot split out94.6%−$22.53M
2019$34.2M$6.83Mnot split out94.3%−$26.51M
2020$40.76M$7.09Mnot split out87.2%−$31.93M
2021$45.24M$6.76Mnot split out85.0%−$37.19M
2022$33.89M$6.83Mnot split out85.5%−$26.24M
2023$49.92M$222.4Knot split out91.5%−$48.4M
2024$120.64Mnot reported separatelynot reported separately93.9%−$115.91M
2025$122.29Mnot reported separatelynot reported separately89.8%−$117.14M

The equity ratio divides total equity, including non-controlling interests, by total assets. Net debt is debt minus cash and short-term investments; a negative figure means cash exceeds debt. In years without separate goodwill, the table shows the sum of goodwill and intangible assets, because the data do not list goodwill separately there.

Equity and debt

What the company owns and owes

  • Cash & equivalents
  • Equity
  • Debt
Figures as a table
YearCash & equivalentsEquityDebtDebt / Equity
2012$371.91$2.63K$00
2013$1.41M$4.01M$711.93K0.18
2014$171.46K$5.38M$150.41K0.03
2015$2.52M$8.22M$00
2016$427.76K$7.58M$00
2017$2.41M$11.33M$00
2018$22.53M$28.62M$00
2019$26.53M$32.25M$19.05K0
2020$31.95M$35.55M$14.04K0
2021$37.22M$38.44M$32.09K0
2022$26.25M$28.99M$6.52K0
2023$48.4M$45.66M$00
2024$115.91M$113.24M$00
2025$117.14M$109.84M$00

Data status and sources

Score
Daily value of 13 Nov 2026, recalculated nightly
Price
Closing price of 12 Nov 2026
Latest annual report
Fiscal year 2025, period end 31 Dec 2025
Currency
Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = SEK 9.9729)
Source
Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.

Mandatory disclosures for this rating

  • ; time horizon around 12 months
  • Rated Weak, published since 7 Nov 2026 (in the score history since 31 Dec 2016)
  • End-of-day prices, metrics cached for up to 24 hours
  • Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
  • Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
  • Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.

MEQIRI counts visits without cookies. With your consent we remember for 90 days where you came from, also in your account, count page changes and time on page, recognise your next visit and load the Meta Pixel, which measures our advertising. You can withdraw your consent at any time under Cookie settings. Privacy